Norursodeoxycholic acid

Drug Profile

Norursodeoxycholic acid

Alternative Names: NorUDCA; Ursodeoxycholic acid homologue

Latest Information Update: 29 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dr Falk Pharma
  • Class Cholic acids; Gallstone therapies; Hepatoprotectants
  • Mechanism of Action Cholesterol inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary sclerosing cholangitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Primary sclerosing cholangitis

Most Recent Events

  • 29 Aug 2017 Chemical structure information added
  • 07 Aug 2017 Dr. Falk Pharma plans a phase III trial for Primary sclerosing cholangitis in Austria (EudraCT2016-003367-19)
  • 01 Aug 2017 Phase-III clinical trials in Primary sclerosing cholangitis in Austria (PO) (EudraCT2016-003367-19)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top